These videos were organized and funded by Biogen and were created for healthcare professionals for the sole purpose of medical education.
At this time, there are no therapies approved directed at tau.
There are investigational drugs in clinical trials and the safety profile and efficacy of those drugs have yet to be established.
The Know Tau program is created and funded by Biogen.
Exploring The Role of Tau in Alzheimer’s Disease – a Red Chair Chat with Brad Dickerson
- explores the role of tau in the healthy brain and in Alzheimer’s disease
- provides an overview of the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS)
- reflects on how our understanding of Alzheimer’s disease has evolved over the past 25 years
Speaker:
Bradley Dickerson11. Director of the Frontotemporal Disorders Unit and The Center for Translational Brain Mapping, Massachusetts General Hospital, Boston, Massachusetts, USA
Moderator:
Ivana Rubino22. Biogen, Massachusetts, USA
References:
1. Apostolova LG et al. The Longitudinal Early-onset Alzheimer’s Disease Study (LEADS): Framework and methodology. Alzheimers Dement. 2021;17(12):2043-55. https://doi.org/10.1002/alz.12350.
2. Cho H et al. Amyloid and tau-PET in early-onset AD: baseline data from the Longitudinal Early-onset Alzheimer’s Disease Study (LEADS). Alzheimers Dement. 2023;19(Suppl 9):S98-114. https://doi.org/10.1002/alz.13453.
3. Atri A et al. Alzheimer’s Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer’s Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care. Alzheimers Dement. 2025;21(6):e14333. https://doi.org/10.1002/alz.14333.
4. Dickerson B et al. The Alzheimer’s Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer’s Disease Related Disorders (DETeCD-ADRD): executive summary of recommendations for specialty care. Alzheimers Dement. 2025;21:e14337. https://doi.org/10.1002/alz.14337.
Plasma Tau Biomarkers and Alzheimer’s Disease
In this video, Suzanne Schindler shares insights from the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) focused on plasma tau biomarkers. She highlights:
- how these biomarkers may help identify Alzheimer’s disease pathology in individuals before symptoms appear
- their correlation to tau pathology in the brain
- how they may be used in clinical research
Speaker:
Suzanne Schindler11. Associate Professor of Neurology, Washington University School of Medicine, St Louis, Missouri, USA
References:
1. Salvadó G et al. Use of plasma p-tau217 to identify Aβ-positive cognitively unimpaired participants for clinical trials: a multicohort study. 17th Clinical Trials on Alzheimer’s Disease (CTAD) Madrid, Spain, October 29 – November 1, 2024: Conference proceedings. JPAD. 2025;12(1):100043. https://doi.org/10.1016/j.tjpad.2024.100043.
2. Horie K et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease. Nat Med. 2023;29(8):1954-63. https://doi.org/10.1038/s41591-023-02443-z.
Biogen-264842
Date of preparation: August 2025
